Elevance Health 10-Qquarter ended 2026-09-30

Executive Summary

Elevance Health sells health coverage to employers, individuals and government programs, and earns pharmacy and care-service revenue through Carelon. It is expanding integrated physical, behavioral and home-based care while repositioning Medicare Advantage and modernizing its operating model. Q3 showed Carelon growth offsetting weaker insurance profitability, while higher investment income helped net income rise 15%. The opportunity is to build a larger care-services business around its insurance relationships; the investment question is whether that growth can overcome medical-cost pressure, shrinking insured membership and government-payment uncertainty.

What's Happening in the Business

• Membership mix: Medical membership fell 1.1% Y/Y to 44.9M, with Medicare Advantage down 16% and Medicaid down 4.9%. Medicaid eligibility redeterminations and deliberate Medicare Advantage repositioning drove losses, while employer fee-based membership grew. Higher premium yields supported revenue despite fewer insured members.
• Carelon expansion: Specialty pharmacy supported CarelonRx profitability, while risk-based specialty, behavioral and home-based care supported Carelon Services. Services growth relied primarily on affiliated business, so it does not represent wholly independent external demand. Modification of an unaffiliated care-delivery contract also reduced benefit expense.
• Pharmacy partnership: CarelonRx’s new CVS agreement runs from 1/2027 through 12/2031, subject to early termination rights, extending a major operating relationship as pharmacy revenue grows through higher revenue per prescription rather than prescription volume.
• Operating-model transformation: Management’s 2026–2027 program combines organizational simplification, workforce changes and technology modernization, including artificial intelligence. Costs reached $147M through 9M, with cash payments expected through 2028; savings must be judged separately from these implementation costs.

Key Financial Highlights

• Segment scope: Revenue includes affiliated activity and therefore does not sum to consolidated revenue. Higher medical costs and technology investment weakened Health Benefits despite premium increases.
• Earnings quality: Q3 net investment income rose to $1.04B from $625M, and lower intangible-asset amortization also supported earnings. The 9M result included a $935M Medicare Advantage risk-adjustment accrual.
• Cash conversion: 9M FCF was $6.72B after $789M of capital expenditures. The $5.36B favorable movement in accounts payable and other liabilities explains much of OCF’s excess over net income and should not be treated as recurring earnings.
• Capital return: Repurchases totaled $1.69B, while shares outstanding fell a net 4.6M, or 2.1%, after issuance. Dividends added $1.12B.
• Investment valuation: Gross unrealized fixed-maturity losses rose to $1.56B from $494M at year-end, primarily because of elevated interest rates; improved investment income therefore coexisted with weaker portfolio valuations.

Risk Assessment

• Medical costs and reserve estimates: Higher Medicaid acuity and utilization, Individual marketplace morbidity and delayed rate adjustments can outpace premiums; 9M earnings also benefited from $1.30B of favorable prior-period claims development that may not recur.
• Government-program economics: Expired enhanced marketplace subsidies and forthcoming Medicaid eligibility changes threaten enrollment, while the share of Medicare Advantage members in plans qualifying for higher-quality payments falls from ≈55% for 2027 to ≈49% for 2028.
• Legal and payment disputes: The Medicare risk-adjustment accrual retained $593M unpaid, with ultimate liability estimated at ≈$320M above or below the original accrual; No Surprises Act disputes create additional uncertainty.
• Pharmacy regulation: Proposed changes to rebates, reporting and Medicare Part D compensation could alter CarelonRx economics just as it becomes a larger profit contributor.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Insurance repricing: Health Benefits’ operating gain fell despite premium increases. Later filings should show whether rates catch up with Medicaid medical costs, or whether membership losses and margin pressure persist.
• Carelon growth quality: Both Carelon segments improved quarterly profits, but Services growth relied heavily on affiliates. Sustained specialty, behavioral and home-care gains would support the strategy; weaker contract results would undermine it.
• Medicare Advantage repositioning: Membership is contracting and future quality-bonus eligibility is lower. Stabilizing enrollment with better profitability would validate the repositioning; continued contraction without margin recovery would not.
• Transformation payoff: The program is incurring costs through a period of elevated operating expenses. Success means lower ongoing expense pressure without damage to revenue or care delivery, rather than earnings improvement solely from charges ending.